Stopping therapy safely in ulcerative colitis with no inflammation
Part of Digestive system clinical trials.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and have had ulcerative colitis for at least 3 years.
- Your last colonoscopy within the past year showed no signs of active inflammation (both inside the colon and under the microscope).
- You must be in remission without any symptoms, elevated inflammation markers, or recent changes in your therapy.
- You cannot have active inflammation, recent steroid use, or a history of certain liver or colon conditions.
- You must be able to follow the study's schedule for sample collection and check-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether it is safe to stop taking an immunosuppressant medication in older adults (60+) with ulcerative colitis that has been in remission for a long time. By stopping the drug, they hope to reduce side effects while keeping the disease under control.
This study looks at whether it's safe to stop taking mesalamine (a drug that helps control inflammation in the gut) for people with ulcerative colitis or Crohn's disease who are already on stronger treatments like biologics or immunomodulators. If you're doing well, this might reduce your daily pill burden.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
This study tests whether monitoring ulcerative colitis with stool-based markers—simple, non-invasive tests—can help guide treatment as effectively as the usual care approach. It aims to see if this strategy helps you stay in remission and avoid flare-ups.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.